<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Artificial Intelligence | Tissuepathology.com</title>
	<atom:link href="https://tissuepathology.com/category/digital-pathology-news/artificial-intelligence/feed/" rel="self" type="application/rss+xml" />
	<link>https://tissuepathology.com</link>
	<description>Educational and informative</description>
	<lastBuildDate>Wed, 12 Aug 2026 12:57:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://tissuepathology.com/wp-content/uploads/2017/07/cropped-Portrait_640x960px-32x32.png</url>
	<title>Artificial Intelligence | Tissuepathology.com</title>
	<link>https://tissuepathology.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Proscia: Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx</title>
		<link>https://tissuepathology.com/2026/08/12/proscia-keeping-digital-pathology-open-the-regulatory-framework-behind-concentriq-ap-dx/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Wed, 12 Aug 2026 12:57:04 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Blogs]]></category>
		<category><![CDATA[Clinical Laboratories]]></category>
		<category><![CDATA[Data Management]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Laboratory Information Systems]]></category>
		<category><![CDATA[Laboratory Management & Operations]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Whole slide]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Blog]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[FDA 510(k) Clearance]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Laboratory Information System]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Proscia]]></category>
		<category><![CDATA[Software]]></category>
		<category><![CDATA[Whole Slide Scanners]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24606</guid>

					<description><![CDATA[<p>From the Proscia blog: Interoperability in digital pathology is about more than the ability to open an image file. It means giving pathologists a consistent, trusted experience as laboratories add scanners, displays, and connected systems. Selecting a digital pathology platform for primary diagnosis is a long-term, important decision impacting lab operations and the patients who [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/12/proscia-keeping-digital-pathology-open-the-regulatory-framework-behind-concentriq-ap-dx/">Proscia: Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Leica Biosystems Enables Faster Cancer Diagnoses Through Multiple Digital Pathology FDA Clearances, Including Industry-First AI-Assisted Quality Control Software</title>
		<link>https://tissuepathology.com/2026/08/11/leica-biosystems-enables-faster-cancer-diagnoses-through-multiple-digital-pathology-fda-clearances-including-industry-first-ai-assisted-quality-control-software/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Tue, 11 Aug 2026 12:56:37 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Clinical Laboratories]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[Whole slide]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[AI-Assisted Quality Control Software]]></category>
		<category><![CDATA[cancer diagnoses]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[FDA 510(k) Clearance]]></category>
		<category><![CDATA[FDA clearance]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[leica biosystems]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[U.S. Food and Drug Administration]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24603</guid>

					<description><![CDATA[<p>Leica Biosystems: Portfolio expansion marks new era for diagnosis delivery, translating digital pathology innovation to clinical impact by accelerating workflows and patient care VISTA, Calif., August 11, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced multiple U.S. Food and Drug Administration (FDA) 510(k) clearances [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/11/leica-biosystems-enables-faster-cancer-diagnoses-through-multiple-digital-pathology-fda-clearances-including-industry-first-ai-assisted-quality-control-software/">Leica Biosystems Enables Faster Cancer Diagnoses Through Multiple Digital Pathology FDA Clearances, Including Industry-First AI-Assisted Quality Control Software</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>StatLab: The cost of slide choice in digital pathology.</title>
		<link>https://tissuepathology.com/2026/08/10/statlab-the-cost-of-slide-choice-in-digital-pathology/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Mon, 10 Aug 2026 11:50:49 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Blogs]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Whole slide]]></category>
		<category><![CDATA[adhesion slides]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[StatLab]]></category>
		<category><![CDATA[whole slide imaging]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24601</guid>

					<description><![CDATA[<p>The latest from StatLab Background Whole slide imaging (WSI) is gaining widespread adoption in diagnostic and research pathology. While attention is often given to image clarity and scanner performance, the microscope slide itself can be an influential factor in digital pathology. Background staining, an artifact arising from residual stain retained on slide surfaces, can affect [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/10/statlab-the-cost-of-slide-choice-in-digital-pathology/">StatLab: The cost of slide choice in digital pathology.</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan</title>
		<link>https://tissuepathology.com/2026/08/07/proscia-receives-new-fda-510k-clearance-for-concentriq-ap-dx-with-predetermined-change-control-plan/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Fri, 07 Aug 2026 12:16:20 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[501(k) clearance]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Predetermined Change Control Plan]]></category>
		<category><![CDATA[Proscia]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24599</guid>

					<description><![CDATA[<p>PHILADELPHIA — August 6, 2026 — Proscia® has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Concentriq® AP-Dx. The clearance includes compatibility with the Leica Aperio® GT 450 DX slide scanner, cloud deployment, and a Predetermined Change Control Plan (PCCP). Concentriq AP-Dx is a digital pathology platform for primary diagnosis used by laboratories [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/07/proscia-receives-new-fda-510k-clearance-for-concentriq-ap-dx-with-predetermined-change-control-plan/">Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Indica Labs: Open Science Does Not Require Open Source: The Role of Open Pathology in Research</title>
		<link>https://tissuepathology.com/2026/08/06/indica-labs-open-science-does-not-require-open-source-the-role-of-open-pathology-in-research/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Thu, 06 Aug 2026 12:36:50 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Blogs]]></category>
		<category><![CDATA[Clinical Pathology]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Blog]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Indica Labs]]></category>
		<category><![CDATA[Open Pathology]]></category>
		<category><![CDATA[Pathology]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24595</guid>

					<description><![CDATA[<p>From the Indica Labs blog The future of scientific discovery is increasingly shaped by the principles of open science. Researchers around the world are working to make data more accessible, experiments more reproducible, and scientific collaboration more effective. These goals have become especially important in digital pathology, where advances in whole slide imaging, multiplexed tissue [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/06/indica-labs-open-science-does-not-require-open-source-the-role-of-open-pathology-in-research/">Indica Labs: Open Science Does Not Require Open Source: The Role of Open Pathology in Research</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aiforia: Unlocking diagnostic value at Fimlab with Aiforia® Breast Cancer Suite</title>
		<link>https://tissuepathology.com/2026/08/05/aiforia-unlocking-diagnostic-value-at-fimlab-with-aiforia-breast-cancer-suite/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Wed, 05 Aug 2026 13:12:53 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Blogs]]></category>
		<category><![CDATA[Clinical Laboratories]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Health Technology Collaboration]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Aiforia]]></category>
		<category><![CDATA[Blog]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[Fimlab]]></category>
		<category><![CDATA[Finland]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Philips]]></category>
		<category><![CDATA[Softwarepoint]]></category>
		<category><![CDATA[workflow]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24593</guid>

					<description><![CDATA[<p>From the Aiforia blog: In modern clinical pathology, adopting artificial intelligence (AI) is no longer just about algorithm accuracy. A key success factor is seamless workflow integration. Pathology departments manage high sample volumes under strict turnaround times, with vendor lock-in and fragmented software as major obstacles to scaling their digital pathology workflows. Last June, at [&#8230;]</p>
The post <a href="https://tissuepathology.com/2026/08/05/aiforia-unlocking-diagnostic-value-at-fimlab-with-aiforia-breast-cancer-suite/">Aiforia: Unlocking diagnostic value at Fimlab with Aiforia® Breast Cancer Suite</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
